Loading
A phase 1/2 trial of Palbociclib, Ribociclib, Abemaciclib and Everolimus in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC is a phase 1/2 interventional study registered as NCT07002177 by Forward Pharmaceuticals Co., Ltd., with 196 participants planned, started 2025-06-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG and Everolimus 10 mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Forward Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Everolimus, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
Shares Abemaciclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/